Impact of COVID-19 on Mental, Neurological and Substance Use Services: Results of a Rapid Assessment
10/05/2020 12:00 AM EDT
Source: World Health Organization (WHO). Published: 10/5/2020. This 48-page report of a survey completed by 130 countries during the period June-August 2020 provides information about the extent of disruption to mental, neurological, and substance use services due to COVID-19; the types of services that have been disrupted; and how countries are adapting to overcome these challenges. (PDF)
10/02/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 10/2/2020. This four-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Sofia 2 Flu + SARS Antigen FIA. The Sofia 2 Flu + SARS Antigen FIA is authorized for use with certain respiratory specimens collected from individuals suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider within the first five days of the onset of symptoms. (PDF)
10/02/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 10/2/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the OmniPATH COVID-19 Total Antibody ELISA Test. The OmniPATH COVID-19 Total Antibody ELISA Test is authorized for the detection of total antibodies (including IgM/IgG/IgA) to SARS-CoV-2 in human serum. (PDF)
10/02/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 10/2/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ). The BioFire RP2.1-EZ is authorized for use with nasopharyngeal swab specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
10/02/2020 12:00 AM EDT
Source: National Emerging Special Pathogens Training and Education Center (NETEC). Published: 10/2/2020. This 56-minute webinar discusses the importance of personal protective equipment (PPE) in the First Responder Environment, techniques to deal with PPE fatigue, and how to improve compliance. The presenters answer questions from participants, including about PPE requirements in the office, ambulance, and firehouse. (Video or Multimedia)
10/01/2020 12:00 AM EDT
Source: European Union, European Centre for Disease Prevention and Control (ECDC). Published: 10/1/2020. The R-based tool epitweetr allows users to automatically monitor trends of tweets by time, place and topic, with the aim of detecting public health threats early through signals, such as an unusual increase in the number of tweets. It was designed to support public health experts with the early detection of threats from infectious diseases but can be extended to all hazards and other fields of study by modifying the topics and keywords. (Text)
10/01/2020 12:00 AM EDT
Source: Infectious Diseases Society of America (IDSA). Published: 10/2020. This web page, developed with the Centers for Disease Control and Prevention (CDC), reviews research and guidance on the use of masks, face coverings, and eye protection, as well as strategies that include physical distancing and isolation during the COVID-19 pandemic. It covers Eye Protection, Isolation and Infection Control, Masks and Face Coverings for the Public, Personal Protective Equipment in Medical Settings, and Physical Distancing. (Text)
10/01/2020 12:00 AM EDT
Source: Infectious Diseases Society of America (IDSA). Published: 10/2020. This collection of COVID-19 diagnostic resources, developed with the Centers for Disease Control and Prevention (CDC), is designed for clinicians, clinical microbiologists, and other laboratory science professionals. Resources are provided for Antibody Testing, Rapid Testing, and RT-PCR Testing. (Text)
10/01/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 10/1/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of a Molecular LDT COVID-19 Authorized Test called the UMass Molecular Virology Laboratory 2019-nCoV rRT-PCR Dx Panel that has been issued an Emergency Use Authorization (EUA) by the FDA. The Molecular LDT COVID-19 Authorized Test is authorized for use on certain respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
09/29/2020 12:00 AM EDT
Source: European Union, European Centre for Disease Prevention and Control (ECDC). Published: 9/29/2020. This 44-page, fifth consecutive report of the European Union Laboratory Capability (EULabCap) monitoring program presents European Union/European Economic Area (EU/EEA) laboratory capabilities and capacities in 2018, and the trends of previous survey results over the period 2013–2018. (PDF)
09/25/2020 12:00 AM EDT
Source: European Union, European Centre for Disease Prevention and Control (ECDC). Published: 9/25/2020. This eight-page report provides information about pertussis cases in 2018, when there were 35,627 cases of pertussis reported by 30 European Union/European Economic Area (EU/EEA) countries. Five countries - Germany, the Netherlands, Norway, Spain, and the United Kingdom (UK) - accounted for 72 percent of all notified cases. (PDF)
09/24/2020 12:00 AM EDT
Source: Michigan State University (MSU). Published: 9/24/2020. This one-hour, two-minute webinar seeks to summarize challenges with opioid and other substance misuse, emphasizing related problems for rural communities in the wake of COVID-19; highlight opportunities to address these challenges through science-based prevention programming, using illustrations from work on virtual trainings to enhance resilience; and share recent developments in capacity building for science-based prevention programming in rural communities, focusing on the National Behavioral Health Extension Network (NBH E-Net). (Video or Multimedia)
09/01/2020 12:00 AM EDT
Source: American Foundation for the Blind (AFB). Published: 9/2020. This 94-page report provides information and results from a survey that investigated the experiences of participants who are blind or have low vision during the start of the COVID-19 pandemic to determine how they were affected in areas that include access to transportation, healthcare, access to food and supplies, employment, education, and voting. (PDF)
07/08/2020 12:00 AM EDT
Source: United Nations Office for the Coordination of Humanitarian Affairs, Inter-Agency Standing Committee (IASC). Published: 7/8/2020. This one-hour, 32-minute webinar explores the impacts of COVID-19 on women and girls, and strengthens understanding of gender issues in humanitarian action through real stories on the ground, shared by expert panelists, and an interactive discussion with participants. It also explores the global, regional, and field efforts to address these gender concerns. (Video or Multimedia)
06/26/2020 12:00 AM EDT
Source: United Nations Office for the Coordination of Humanitarian Affairs, Inter-Agency Standing Committee (IASC). Published: 6/26/2020. This one-hour, 13-minute webinar provides an overview of tools developed by the IASC Reference Group on Mental Health and Psychosocial Support (MHPSS) in Emergency Settings (chaired by WHO and IFRC) to support the COVID-19 response. It features presentations from co-chairs of two country-level MHPSS Technical Working Groups in Afghanistan and Nigeria about their experience scaling up support on the ground with these tools. (Video or Multimedia)
06/24/2020 12:00 AM EDT
Source: European Union, European Medicines Agency (EMA). Published: 6/24/2020. This 54-page document provides a risk management plan (RMP) to ensure rigorous safety monitoring of remdesivir once authorized across the European Union (EU). Remdesivir has broad-spectrum activity against members of the coronaviruses (CoVs), including Severe Acute Respiratory Syndrome (SARS) SARS-CoV-2. (PDF)
06/16/2020 12:00 AM EDT
Source: United Nations Office for the Coordination of Humanitarian Affairs, Inter-Agency Standing Committee (IASC). Published: 6/16/2020. In this one-hour webinar, expert panelists provide an overview of the Interim Guidance on the Emergency Response Preparedness Approach to the COVID-19 Pandemic, and examples of its field application, including a presentation on how national actors are tackling this in Bangladesh. (Video or Multimedia)
05/07/2020 12:00 AM EDT
Source: United Nations Office for the Coordination of Humanitarian Affairs, Inter-Agency Standing Committee (IASC). Published: 5/7/2020. This one-hour webinar looks at how the humanitarian community is working to reduce the risks that women and children face and the risk of sexual exploitation and abuse, and to support the most vulnerable, including challenges during the COVID-19 pandemic. (Video or Multimedia)
04/28/2020 12:00 AM EDT
Source: European Union, European Medicines Agency (EMA). Published: 4/28/2020. This 21-page document provides points that are intended to provide guidance and clarity for all parties involved in clinical trials during the COVID-19 pandemic. The simplification measures proposed in this document will last only during the current public health crisis until the revocation of this guidance, when there is a consensus that the period of the COVID-19 outbreak in the European Union/European Economic Area has passed. (PDF)
.png)
No hay comentarios:
Publicar un comentario